From William N. Hait, MD, PhD, Global Therapeutic Area Head, Oncology, Johnson & Johnson Pharmaceutical Research & Development
Cancer. It’s a disease that affected an estimated 15 million people in 2010. That number is projected to rise dramatically to 27 million by 2030, according to the World Health Organization. These numbers are indicative of a public health concern that deserves to be a priority.
Throughout Johnson & Johnson, there are people who are working to combat cancer and its effects, whether through innovative products or collaborations, such as a recent partnership between Veridex and Massachusetts General Hospital, to develop technology to capture, count and characterize tumor cells found in patients’ blood. This collaboration, which also involves Ortho Biotech Oncology Research & Development, a unit of Johnson & Johnson Pharmaceutical Research & Development, has been discussed on JNJ BTW before…it aims to develop a next-generation, automated diagnostic test that’s can detect a cancer cell from a billion blood cells. The test will be strong enough to reveal the biology of cells at the DNA, RNA and protein levels.
In all segments of our business, pharmaceuticals, consumer and medical devices & diagnostics, we are using our expertise to address cancer. Today, we join individuals and organizations around the world in recognizing World Cancer Day.